- Inositol-polyphosphate
multikinase (EC 2.7.1.151, IpK2, IP3/IP4 6-/3-kinase, IP3/IP4 dual-specificity 6-/3-kinase, IpmK, ArgRIII, AtIpk2alpha, AtIpk2beta...
-
cancer cells.
Existing molecules fall in two main categories: the
older multikinase inhibitors and the more
recent selective inhibitors.
Although RET alterations...
- to ****ociate with the
protein kinases Ste11, Ste7, and Fus3 to form a
multikinase complex.
Scaffold proteins act in at
least four ways:
tethering signaling...
-
impact on QoL
compared with the
commonly seen side-effects with oral
multikinase inhibitors. Temsirolimus' high
level of
specificity for mTOR
likely contributes...
-
promising treatment approaches for PRCC.
Foretinib is one
example of a
multikinase inhibitor targeting c-MET.
Considering that MET gene
mutation is one...
- (2008). "Hand foot skin
reaction in
cancer patients treated with the
multikinase inhibitors sorafenib and sunitinib". J. Ann. Oncol. 19 (11): 1955–61...
-
reversible posterior leucoencephalopathy syndrome (uncommon).
Axitinib PO
Multikinase inhibitor.
Renal cell
carcinoma Hypertension,
thyroid dysfunction, blood...
-
tumor progression after local treatments. In 2007, sorafenib, an oral
multikinase inhibitor, was the
first systemic agent approved for first-line treatment...
- by
adding a
phosphate group with the help of Inositol-polyphosphate
multikinase (IPMK). It is
believed to be one of the many
second messengers in the...
-
Llovet JM,
Lynch M (October 2008). "Preclinical
overview of sorafenib, a
multikinase inhibitor that
targets both Raf and VEGF and PDGF
receptor tyrosine kinase...
